August 2012
-
Meissa Vaccines announced that the FDA has cleared the company’s IND for a Phase 1 clinical study of its MV-014-212 intranasal live attenuated vaccine candidate against SARS-CoV-2. The company announced that it had held a pre-IND… Read more . . .
-
Ampio Pharmaceuticals said that preliminary results from its AP-014 Phase 1 clinical trial of inhaled Ampion for the treatment of COVID-19 demonstrate a significant reduction in all-cause mortality and shorter hospital stays for patients receiving Ampion… Read more . . .
-
In an expansion of a manufacturing agreement between Altimmune and Lonza that was announced in November 2020, Lonza has agreed to dedicate a manufacturing suite at its Texas facility for production of Altimmune’s AdCOVID intranasal… Read more . . .
-
Canadian biotech SaNOtize said that a Phase 2 trial of its nitric oxide nasal spray (NONS) in COVID-19 patients demonstrated that the nasal spray reduced viral load by about 95% within 24 hours post dose… Read more . . .
-
Copley Scientific, which recently made multiple updates to its range of OINDP testing equipment, has announced the launch of a new range of accessories for testing nasal sprays, including metered dose and dry powder nasal… Read more . . .
-
After having to make a last-minute switch to an online format in 2020, the organizers of the annual Respiratory Drug Delivery (RDD meeting) had more time to plan a virtual meeting for 2021, and they… Read more . . .
-
The US Patent and Trademark Office has issued US Patent No. 10,933,204, titled “Prescription bottle cap capable of administering opioid overdose reversal agent” to CounterAct for its naloxone nasal spray cap, the company said. CounterAct… Read more . . .
-
DPI developer Iconovo announced that it has received its first patent in India covering the company’s ICOone single dose DPI. According to the company, the ICOone platform is already covered by patents in Europe, and patents… Read more . . .
-
Neurelis announced that it has raised $114 million in a Series D preferred stock financing to fund commercialization of Valtoco diazepam nasal spray, which was approved by the FDA for the treatment of seizure clusters or acute repetitive… Read more . . .
-
TFF Pharmaceuticals has announced agreements for feasibility studies with vaccine developer GreenLight Biosciences and with NeuroRx. TFF is performing studies to determine if dry powder formulations of GreenLight’s mRNA COVID-19 vaccine candidate and NeuroRx’s Zyesami… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.